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1. SUMMARY 
1.1 Deutsche Zusammenfassung 
Die Leberfibrose als gemeinsame Endstrecke aller chronischen Lebererkrankungen 
führt zur Leberzirrhose, der zehnthäufigsten Todesursache in Deutschland, für die bis 
auf die Lebertransplantation - keine effektiven Präventions- und Therapieoptionen zur 
Verfügung stehen. Aktuelle genomweite Assoziationsstudien haben den 
Polymorphismus p.I148M des Adiponutrin-Gens (PNPLA3) als Risikofaktor für nicht-
alkoholische und alkoholische Lebererkrankungen identifiziert. Die PNPLA3-Variante 
p.148M ist mit einem erhöhten Progressionsrisiko für diese Erkrankungen und mit 
erhöhten Transaminasenaktivitäten assoziiert. Ziel der aktuellen Studie ist es, 
Adiponutrin als genetischen Risikofaktor für die Leberfibrose zu untersuchen. Hierzu 
wurde die Lebersteifigkeit in einer großen Kohorte von 899 Patienten mit 
unterschiedlichen Lebererkrankungen nicht-invasiv mittels transienter Elastographie 
quantifiziert. Die transiente Elastographie korrelierte mit der Leberhistologie (ρ = 0.743, 
P < 0.01). Die Adiponutrin-Variante p.I148M war signifikant mit der Lebersteifigkeit 
assoziiert (P = 0.017). Patienten, die das Risikoallel p.148M trugen, wiesen ein erhöhtes 
Risiko (OR = 1.56, P = 0.005) für eine Leberzirrhose (definiert als Lebersteifigkeit ≥ 13.0 
kPa) auf. Interessanterweise erhöhte der PNPLA3-Polymorphismus das Fibroserisiko 
sowohl in der gesamten Kohorte als auch bei Patienten mit viralen oder nicht-viralen 
Hepatitiden. Insgesamt ließen sich durch den genetischen Risikofaktor 16% des 
gesamten Risikos, an einer Leberzirrhose zu erkranken, erklären. Diese Ergebnisse 
belegen die Bedeutung der Adiponutrin-Variante für die Progression einer Leberfibrose. 
Die Studie zeigte, dass genetische Untersuchung bei Patienten, die mittels nicht-
invasiver Elastographie phänotypisiert wurden, relevante Ergebnisse erzielen, die 
eventuell in zukünftige Überwachungsstrategien für Risikopatienten integriert werden 
können. 
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1.2 Abstract 
Liver fibrosis is the common consequence of chronic liver injury and inevitably leads to 
liver cirrhosis, which is the tenth most common cause of death in Germany. To date no 
effective preventive and therapeutic options, except for liver transplantation, are 
available for patients suffering from cirrhosis. Recent genome-wide association studies 
have identified the p.I148M adiponutrin (PNPLA3) variant as risk factor for severe forms 
of non-alcoholic and alcoholic liver diseases. The PNPLA3 allele p.148M confers an 
increased risk for fatty liver disease and elevated serum aminotransferase activities 
reflecting liver injury. In the current elastography-based observational cross-sectional 
study we aimed to investigate adiponutrin as a genetic determinant of liver fibrosis, the 
hallmark of all chronic liver diseases. Therefore we staged 899 patients with different 
chronic liver diseases non-invasively by transient elastography (Fibroscan) and 
genotyped them for variant adiponutrin (rs738409) by PCR-based assays. A subgroup 
of 229 patients consented to percutaneous liver biopsy, validating the accuracy of 
elastography in staging fibrosis (ρ = 0.743, P < 0.01). Genotyping results proved that 
carriers of distinct p.I148M adiponutrin genotypes display significant (P = 0.017) 
differences in liver stiffness determined by elastography. In particular, individuals 
carrying the allele p.148M are at higher risk of developing liver cirrhosis defined by 
stiffness values ≥ 13.0 kPa (OR = 1.56, P = 0.005). Of note, the PNPLA3 risk variant 
advances fibrosis in the total cohort as well as in the subgroups of patients with viral 
hepatitis and non-viral liver diseases and contributes 16% of the total cirrhosis risk. In 
conclusion, our study shows that the adiponutrin risk variant is a common genetic 
determinant of progressive liver fibrosis. This is the first study showing that clinically 
relevant genetic investigations in patients with chronic liver disease can be performed in 
cohorts phenotyped with transient elastography, and based on these results non-
invasive follow-up strategies for these individuals can be envisioned. 
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1.3 Abbreviations 
ALD, alcoholic liver disease; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; 
AUC, area under the curve; BMI, body mass index; CI, confidence interval; FFA, free 
fatty acid; gamma-GT, γ-glutamyl transferase; GWAS, genome-wide association study; 
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HWE, 
Hardy-Weinberg equilibrium; I, isoleucine; INR, international normalised ratio; kPa 
kilopascal; M, methionine; MELD, model of end-stage liver disease;  NAFLD, non-
alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OR, odds ratio; PAF, 
population attributable fraction; PBC, primary biliary cirrhosis; PCR, polymerase chain 
reaction; PNPLA3, patatin-like phospholipase domain containing 3 (adiponutrin); PPAR, 
peroxisome proliferator activated receptor; PSC, primary sclerosing cholangitis; SNP, 
single nucleotide polymorphism; SREBP1c, sterol response element binding protein 1c; 
TE, transient elastography; TG, triglicerydes; TNF, tumor necrosis factor. 
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2. INTRODUCTION 
 
2.1 Hepatic fibrosis – a complex process determined by genetic factors 
Liver fibrosis (or liver scarring), a hallmark of chronic liver diseases, is characterized by 
excessive deposition of collagen and of other extracellular matrix proteins in the liver 
leading to a progressive deterioration of hepatic function (Bataller R 2005, Friedman SL 
2008). According to the latest studies chronic hepatitis C infections, alcoholic liver 
disease (ALD) and non-alcoholic steatohepatitis represent the main causes of liver 
fibrosis in developed countries. Based on the underlying liver disease, the distribution of 
lesions and the fibrotic mechanisms, distinct patterns of liver fibrosis have been 
described (Hernandez-Gea V 2011). However, regardless of the causative factor 
triggering hepatic fibrogenesis, chronic liver injury leads inevitably to progresive fibrosis 
(Friedman SL 2010). Once in the cirrhotic phase, the natural history of liver destruction 
includes a progression from compensated to decompensated disease. The latter one is 
characterised by portal hypertension, liver failure and ultimately the death of the patient, 
if not transplanted. It is worth noting that in the past decades cirrhosis mortality rates 
have increased dramatically in Europe and currently reach 33 cases per 100.000 
German males yearly (Leon DA 2006). In developing countries cirrhosis mortality rates 
are also increasing and according to the latest data they exceed 23 cases per 100.000 
Polish males yearly (Zatoński WA 2010)  
Liver is one of the most complex organs with a high level of functional variability. 
Among several liver functions clearance of xenobiotics and endobiotics, synthesis of 
proteins and energy storage represent only some of its multiple tasks. Thus, only a 
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minor number of liver conditions are monogenic. The most common liver diseases are 
complex, as they are determined by a combination of genetic and environmental risk 
factors. The complexity of the genes expressed in the hepatic cells, their interactions 
and function is a major challenge in determining the pathogenesis of complex 
hepatopathies. In the recent years, genotyping of over 500,000 single nucleotide 
polymorphisms (SNPs) that cover more than 75% of the human genome, in large 
cohorts of individuals with specific liver conditions, have led to the identification of 
several loci. Indeed, such an approach used in genome wide association studies 
(GWAS), has enabled the identification of the causative genes involved in several liver 
diseases. Among hepatic conditions with unraveled genetic background, fatty liver 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH), viral hepatitis, primary 
biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result in hepatic fibrosis 
as a result of a chronic liver injury. 
Conceptually liver fibrogenesis is a complex (i.e. multifactorial) process governed 
by multiple genetic factors and their interactions with numerous environmental 
determinants. The non-genetic triggers leading to liver fibrogenesis (e.g. viral hepatitis, 
excessive alcohol consumption, fatty liver disease, autoimmune liver diseases) have 
been well described; nevertheless as the progression of liver fibrosis varies markedly 
between individuals with similar risk profiles, genetic factors are likely to represent 
critical determinants of this process (Hillebrandt 2005). Hence, the identification of 
profibrogenic genetic variants is crucial for detecting at-risk individuals and for designing 
tailored preventive strategies (Krawczyk M 2010b). As shown in Figure 1, based on the 
prevalence and penetrance of genetic variants, several approaches can be applied. For 
example, an Australian candidate-gene study (Richardson MM 2005) identified an 
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association between polymorphisms in six loci (APOE, CCR5, CTLA4, HFE, MTTP, 
SOD2) and progression of liver fibrosis in patients with chronic hepatitis C virus (HCV) 
infection. On the other hand, Huang et al. (Huang H 2007) used a machine-learning 
approach to analyse results from a large genome wide-association study (GWAS) in 
1020 HCV patients and identified a polygenic risk score of hepatic fibrosis including 
seven polymorphisms (AP3S2, AQP2, AZIN1, DEGS1, STXBP5L, TLR4, TRPM5). The 
OR (odds ratio) among carriers of at least five risk alleles from the first study 
(Richardson MM 2005) reached 24, and area under the curve (AUC) statistics of the 
cirrhosis risk score from the second study (Huang H 2007) was 0.73. Of note, both 
studies identified different variants as putative determinants of liver fibrosis in 
comparable cohorts (Huang H 2007, Richardson MM 2005). Hence, the results remain 
inconclusive, attempts to unravel the host genetic background of hepatic fibrosis in 
humans have met with limited success, and no common susceptibility variants have 
been identified so far (Weber S 2008, Guo J 2009, Marcolongo M 2009, Wasmuth HE 
2009).  
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Figure 1. Relationship between frequencies of susceptibility variants and phenotypes. In 
case of Mendelian diseases, which are mostly caused by rare mutations, the causative 
variant confers a high risk for developing a disease. The low-frequency alleles that 
associate with intermediate risk as well as rare variants with low disease risk can be 
identified by resequencing techniques. Genetic risk variants identified by GWAS 
represent the common alleles that are associated with a low disease risk.  
Adapted from Krawczyk M 2010b. 
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2.2 Measurement of liver fibrosis: the invasive approach 
Assessment of liver fibrosis in patients with chronic liver diseases is crucial for diagnosis 
and prognosis. To date this is accomplished mostly by liver biopsy, which represents the 
“gold standard” for staging hepatic fibrosis (Rockey DC 2009). In this procedure liver 
specimens are obtained either percutaneously or via a vascular (transiugular) route. In 
rare cases a laparoscopic liver biopsy is performed. After the procedure the achieved 
hepatic specimens are examined microscopicaly by a pathologist to assess liver injury. 
Depending on the underlying disease distinct histological patterns of liver fibrosis can be 
recognised. Therefore, pathologists use various scoring systems, for example the 
Desmet and Scheuer score (Desmet VJ 1994) in patients with chronic hepatitis, 
whereas in NAFLD the Brunt scoring system (Brunt EM 1999) has been applied. 
Although liver biopsy is regarded as the mainstay for staging hepatic fibrosis, it has 
limitations such as procedure-related bleeding (Terjung B 2003), sampling errors, 
observer variability, and lack of subclassification of cirrhosis (Bedossa P 2003, Castéra 
L 2010b). As a result, previous genetic or intervention studies of hepatic fibrosis have 
been hampered by small study sizes, since participants had to undergo invasive liver 
biopsies for histological assessment of liver status (Bataller R 2003, Weber S 2010). 
Lately the International Fibrosis Group has recommended that non-invasive surrogate 
markers reproducibly detecting changes in fibrosis would be helpful to reduce the 
complexity and increase the size of antifibrotic trials (McHutchison J 2006). Therefore, 
non-invasive methods for the assessment of liver fibrosis including direct and indirect 
(surrogate) markers are being evaluated (Grünhage F 2009, Castéra L 2010b).  
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2.3 Quantification of liver fibrosis: the non-invasive approach 
Among alternative approaches, transient elastography (TE) has emerged as a non-
invasive and accepted tool of quantifying liver fibrosis, since it is a rapid, pain- and 
complication-free method with high intra- and interobserver agreement (Pinzani M 2008, 
Castéra L 2010c). In short, TE is performed with an ultrasound transducer probe (Figure 
2) that is mounted on a vibrator. The tip of the transducer is placed on the skin between 
the rib bones at the level of the right lobe of the liver. The vibration of the probe induces 
a shear wave that propagates through the liver. These propagating waves are followed 
by pulse-echo ultrasound acquisitions, and their velocity is directly related to tissue 
stiffness. In other words, the harder and the more fibrotic is the liver, the faster the shear 
wave propagates. The measurement depth ranges between 25 and 65 mm below the 
skin surface. The results are expressed in [kPa], and ten measurements are performed 
in each patient. The median value is taken as representative. This approach has several 
advantages in comparison to liver biopsy. The procedure does not last more than 10 – 
15 minutes, it can be performed by an experienced nurse or a clinician and is virtually 
complications-free. Moreover it is suitable for an ambulant follow-up of patients with 
chronic liver diseases. To date, prospective studies in patients with HBV (Marcellin P 
2009) and chronic HCV (Castéra L 2005) or non-viral hepatitis (Obara N 2008) as well 
as meta-analyses have documented that liver stiffness correlates significantly with 
histological fibrosis stages, in particular the most common technique known as transient 
elastography (Fibroscan®) (Friedrich-Rust M 2009), and exactly defined cut-off values 
for staging of liver fibrosis are being developed (Friedrich-Rust M 2008). In general, the 
cut-off of 13.0 kPa has been proposed that is the most suitable one to distinguish 
between individuals with liver fibrosis and cirrhosis (Friedrich-Rust M 2008). 
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Figure 2: Measurement of liver fibrosis with transient elastography (Fibroscan®). See 
text (p. 16) for detailed explanation.  
 
2.4 Variant Adiponutrin (PNPLA3) – a genetic risk factor for fatty liver 
In 2008, a genome-wide association scan (GWAS) using a dense map of single 
nucleotide polymorphisms (SNPs) (see Figure 1) revealed for the first time an intriguing 
association between the adiponutrin (PNPLA3) gene locus and plasma levels of liver 
enzymes in the general population (Yuan X 2008). Afterwards, another GWAS in 2111 
individuals identified the p.I148M (rs738409) variant of PNPLA3 as genetic risk factor for 
non-alcoholic fatty liver disease (NAFLD) (Romeo S 2008), a finding subsequently 
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confirmed in additional cohorts (Kantartzis K 2009, Kotronen A 2009a, Romeo S 2010, 
Sookoian S 2009, Wagenknecht LE 2011), and extended to alcoholic liver disease 
(ALD) (Tian C 2010, Stickel F 2011). In particular, carriers of the [G] allele showed 
higher hepatic fat contents (as determined by proton magnetic resonance spectroscopy) 
as well as serum activities of alanine aminotransferase (ALT) (Romeo S 2008, Kollerits 
B 2010) and in case of ALD, were at risk of developing liver cirrhosis (Tian C 2010).  
Moreover, adiponutrin variant has been related to glucose metabolism. For example 
analysis Johansson et al. (Johansson LE 2008) demonstrated that carriers of the p.I148 
polymorphism are in general more insulin-resistant at lower BMI whilst carriers of the 
methionine allele are prone to decreased insulin secretion after oral glucose challenge.  
Adiponutrin, a membrane-bound enzyme encoded by the PNPLA3 gene, is a 
481-amino acid protein that contains a highly conserved patatin-like domain at the N 
terminus. It is expressed predominantly in the liver and in the adipose tissue in response 
to lipogenic factors (Kershaw EE 2006, Huang Y 2010). In vitro studies have 
demonstrated that adiponutrin possesses lipid hydrolase and transacylase activities 
(Lake AC 2005, Wilson PA 2006, He S 2010), whereas in vivo it has been shown to 
hydrolyze emulsified triglycerides in lipid droplets (He S 2010). In contrast to constitutive 
PNPLA3 expression in adipose tissue, transcription in the liver is driven by carbohydrate 
overnutrition via the sterol response element binding protein 1c (SREBP1c). As 
postulated by Huang et al. (Huang Y 2010), feeding with carbohydrates increases insulin 
level which subsequently activates SREBP1c through the heterodimer nuclear receptors 
LXR/RXR and leads to transcriptional activation of PNPLA3. Conversely, degradation of 
adiponutrin is inhibited by accumulation of C16:0, C18:0 and C18:1 fatty acids (Huang Y 
2010). Functional analysis of the rs738409 adiponutrin NAFLD/ALD risk variant showed 
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that the resulting amino acid substitution of isoleucine by methionine change at position 
148 disrupts triglyceride emulsifying activity of PNPLA3 in vivo. As a result, carriers of 
the PNPLA3 variant p.148M are at an increased risk of developing hepatic inflammation 
and fatty liver (Krawczyk M 2010a).  
 
2.5 Fatty liver – the most prevalent liver condition 
The currently experienced increase in liver fibrosis and cirrhosis rates in developed 
countries is in part related to the epidemics of fatty liver disease. Indeed fatty liver, also 
known as non-alcoholic fatty liver disease (NAFLD), is the most common liver disorder in 
the Western world (Krawczyk M 2010a). It is characterised by an excessive hepatic fat 
deposition and encompasses benign and more severe patterns of lipid accumulation. 
Non-alcoholic steatohepatitis (NASH) represents the severe, necroinflammatory form of 
NAFLD, which can lead to liver fibrosis and cirrhosis. Currently the incidence of NAFLD 
is raising dramatically with an estimated prevalence of 20 – 40 % in Western countries 
(Loguercio C 2004). Obesity and the so-called ‘metabolic syndrome’ are the most 
prominent non-genetic risk factors for NAFLD (Portincasa P 2006). Indeed, although 
only 2 – 3% of lean individuals are affected by NASH (Neuschwander-Tetri BA 1996), 
some reports state that up to 50% of morbidly obese patients may suffer from 
steatohepatitis (Dam-Larsen S 2004). Of note, up to 10% of NASH patients will develop 
liver cirrhosis within 5 years (Cortez-Pinto H 2003). Interestingly, most of the patients 
with fatty liver present with no specific symptoms. In some cases enlarge liver can be 
found at the examination of the patient, asymptomatic elevation of transaminases is also 
characteristic for patients with NAFLD. Liver ultrasonography detects the so called 
‘bright liver’ in these individuals. Nevertheless ultrasonography does not allow 
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differentiation between benign forms of hepatic fat accumulation and NASH. When 
NASH is suspected, liver biopsy is performed to confirm or exclude the diagnosis. 
According to Brunt et al (Brunt EM 1999) liver status in NASH patients than staged as 
follows: S1 = perivenular, perisinusoidal or pericellular fibrosis, S2 = periportal fibrosis; 
S3 = bridging fibrosis; S4 = cirrhosis.  
The natural course of fatty liver diseases can be highly variable, it has been 
therefore for long suspected that common gene polymorphisms increase the risk of 
fibrosis in a subgroup of subjects with fatty liver. Indeed studies investigating family 
clustering show that at least 20% of individuals with NASH have first degree relatives 
who are also affected with this condition (Wilner IR 2001). Moreover, a high degree of 
concordance in families with respect to non-alcoholic steatohepatitis and cryptogenic 
cirrhosis has been documented (Struben WM 2000). Figure 3 presents the complexity 
of NAFLD pathogenesis. Excessive accumulation of fat in the liver is determined by 
overweight, obesity, increased visceral adiposity, and insulin resistance. In this 
constellation of risk factors, intrahpatic lipid accumulation results from an excessive 
influx of free fatty acids (FFAs) from the adipose tissue, decreased hepatic export of 
FFAs, or impaired FFAs ß-oxidation (Krawczyk M 2010a). Several metabolic 
abnormalities at the hepatic level have been observed in patients with NAFLD. These 
include oxidative stress (Stewart SF 2004, Palmieri VO 2006), impaired mitochondrial 
oxidation (Sanyal AJ 2001, Pessayre D 2001), generation of free oxygen radicals, and 
increased activity of the cytochrome P-450 system (Robertson G 2001). All of these 
contribute to the progressive hepatic accumulation of lipids and to liver fibrosis in NASH 
(Portincasa P 2006).  
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Figure 3. Pathogenesis of fatty liver disease (see text for explanation).  
Abbreviations: FFA, free fatty acids; HCC, hepatocellular carcinoma; PPARs, 
peroxisome proliferator activated receptors; TG, triglicerydes; TNF, tumor necrosis 
factor. Symbols: increased (↑); decreased (↓); stimulatory effect (+); inhibitory effect (-). 
Adapted from Krawczyk M 2010a. 
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2.6 Study outline and specific aims 
Hepatic fat accumulation, either due to NAFLD or ALD, represents one of the most 
frequent conditions leading to liver fibrosis and cirrhosis worldwide (Everhart JE 2009). 
Previous adiponutrin genetic association studies focused on hepatic fat accumulation 
and were exclusively based on cohorts with NAFLD and ALD (Romeo S 2008, Tian C 
2010). Systematic analyses in patients with fatty liver reported that the PNPLA3 variant 
p.I148M is also associated with histological severity (Sookoian 2009) and more 
particularly with fibrosis in an additive pattern as well (Valenti L 2010, Rotman Y 2010, 
Speliotes EK 2010). In the aforementioned studies (Kantartzis K 2009, Kotronen A 
2009a, Sookoian S 2009, Romeo S 2010, Tian C 2010, Wagenknecht LE 2011) patients 
with liver diseases other than NAFLD and ALD have not been investigated with respect 
to the adiponutrin polymorphism, hence its role as a common genetic determinant of 
hepatic fibrosis has remained speculative (Weber S 2010).  
In the current study it was our aim to investigate the role of the adiponutrin variant 
p.I148M as a common determinant of liver cirrhosis and liver fibrosis in general. 
Therefore we recruited a large cohort of patients with different chronic liver diseases, 
who we all staged non-invasively by transient elastography. Our genetic study is the first 
to employ elastography for phenotyping fibrosis, which allowed the recruitment of a large 
cohort of patients. In this elastography-based study, we demonstrate that the adiponutrin 
variant not only predisposes to severe forms of NAFLD and ALD but also markedly 
enhances hepatic fibrosis across different chronic liver diseases. Our results prove that 
carriers of the risk variant are at an increased risk of developing liver cirrhosis in 
general. Hence, we suggest a new surveillance strategy focusing on a genetically 
defined subgroup of patients at risk for advanced liver injury. 
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3 PATIENTS AND METHODS 
 
3.1 Patients 
In this observational cross-sectional study, we recruited 1,000 consecutive European 
individuals (age 17 - 83 years, 547 males) with chronic liver diseases who were referred 
to our department for transient elastography. All patients underwent careful clinical 
examination. Blood samples were drawn from fasted subjects, and liver functions tests 
including serum ALT activities were determined by standard clinical-chemical assays in 
the central laboratory.  
Table 1 summarizes the baseline clinical characteristics of our cohort. We 
recorded data on estimated daily alcohol consumption, and individuals with non-
alcoholic liver disease who also reported a regular high alcohol intake of > 40 g/d in the 
last year were excluded from the study, as described previously (Hillebrandt S 2005, 
Geier A 2004).  
Informed consent was obtained from all patients, and the study was approved by 
the Research Ethics Committee of the University of Bonn. 
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Table 1 
Clinical characteristics of the study cohort 
Variables Subject characteristics 
N (male / female)   899 (547 / 352) 
Age (years) 50 (17 - 83) 
BMI (kg/m2)    24.6 (14.9 - 45.2) 
Primary liver disease (N) 
   HCV  
   ALD 
   HBV  
   PBC / PSC / AIH 
   NAFLD / NASH 
   Haemochromatosis 
   Other liver diseases# 
 
541 (60.2%) 
112 (12.5%) 
  67 (7.5%) 
  67 (7.5%) 
  64 (7.1%) 
  25 (2.8%) 
  23 (2.6%) 
Alcohol consumption (g/24 h)§ 0 (0 - 40), mean ± SD: 6.2 ± 11.0 
Overt cirrhosis 163 (18.1%) 
Transient elastography 
   Liver stiffness (kPa) 
   ≥ 13.0 kPa (N) 
 
6.8 (2.2 - 75.0) 
201 (22.3%) 
Bilirubin (mg/dL) 
Creatinine (mg/dL) 
INR 
MELD 
Albumin (g/L) 
ALT (U/L) 
γ-GT (U/L) 
Glucose (mg/dL) 
Platelets (×109/l) 
  0.6 (0.1 - 6.0) 
  0.9 (0.5 - 5.1) 
  1.0 (0.9 - 2.1) 
 7 (6 - 31) 
43 (3 - 67) 
    38 (12 - 889) 
    56 (8 - 2597) 
    94 (60 - 195) 
  205 (23 - 887) 
Values are given as medians (ranges), unless stated otherwise. # Other liver diseases include cryptogenic 
liver disease (N = 13), biliary atresia (N = 3), Wilson Disease (N = 2), amyloidosis (N = 1), α1-antitrypsin 
deficiency (N = 1), Budd-Chiari syndrome (N = 1), congenital liver disease (N = 1), and sarcoidosis 
(N = 1). § during the 12 months prior to transient elastography. 
Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; ALT, alanine aminotransferase; 
BMI, body mass index; γ-GT, γ-glutamyl transferase; HBV, chronic hepatitis B virus infection; HCV, chronic 
hepatitis C virus infection; INR, international normalised ratio; MELD, model of end-stage liver disease; 
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary 
cirrhosis; PSC, primary sclerosing cholangitis. 
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3.2 Non-invasive phenotypic characterization of liver fibrosis 
Liver fibrosis was assessed by transient elastography (Fibroscan®, Echosens SA, Paris, 
France). In patients with tense ascites, elastography was preceded by large-volume 
paracentesis. Following the criteria by Castéra et al. (Castéra L 2010a), the results were 
called unreliable if the success rate (i.e. the ratio of valid shots to the total number of 
shots) was < 60% or the interquartile range was > 30% of the median value. The 
procedure was considered to have failed when no value was obtained after 10 shots 
(Castéra L 2010a). According to previous studies (reviewed in Pinzani M 2008) and an 
authoritative meta-analysis (Friedrich-Rust M 2008), individuals with liver stiffness 
≥ 13.0 kPa were regarded to suffer from liver cirrhosis (fibrosis stage F4). Overt cirrhosis 
was diagnosed if there were unequivocal clinical, ultrasound, and/or endoscopic 
findings.  
 
3.3 Invasive assessment of liver fibrosis 
A subgroup of individuals (presented in Table 3) was scheduled for liver biopsy. The 
indications of liver biopsy followed recent consensus recommendations (Schirmacher P 
2004, Rockey DC 2009), and the most common reasons were staging of viral hepatitis 
and abnormal liver tests of unknown aetiology or suspicion of cirrhosis. In most cases 
the intercostal technique approach the percutaneus Menghini technique with 1.8 mm 
needles (Hepafix® G15) under ultrasound guidance was employed. The biopsy was 
performed under local anaesthesia in the 8th or 9th intercostal space in the mid-axilllary 
line. In patients with coagulopathies or ascites a transjugular liver biopsy was performed. 
After the procedures patients were observed for 24 hours to exclude complications. For 
histological scoring of liver fibrosis, paraffin embedded 2- to 4-µm liver sections were 
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stained with haematoxylin an eosin as well as Sirius red for collagen (Hillebrandt S 
2005). The pathologist (Prof. Dr. H. P. Fischer, University Hospital Bonn), who was 
blinded to the elastography results, staged hepatic fibrosis according to Desmet and 
Scheuer as follows: F0 = absence of fibrosis; F1 = perisinusoidal and/or portal fibrosis; 
F2 = perisinusoidal and portal/periportal fibrosis; F3 = septal or bridging fibrosis; and F4 
= cirrhosis (Desmet VJ 1994). 
 
3.4 DNA isolation from EDTA anticoagulated blood  
Genomic DNA was isolated from EDTA anticoagulated blood according to the 
membrane-based QIAamp DNA extraction protocol (Qiagen, Hilden, Germany). In short, 
defrosted blood samples of 200 µl were mixed with 20 µl QIAGEN Protease and 200 µl 
Buffer AL by pulse-vortexing for 15 seconds. After incubation at 56 °C for 10 minutes 
and brief centrifugation, 200 µl of 96-100 % ethanol was added to the sample pulse-
vortexed. The mixture was centrifuged at 8000 rpm for 1 minute and 500 µl of Buffer 
AW1 was added. After centrifuging at 8000 rpm for 1 minute 500 µl of Buffer AW2 was 
added and the mixture was centrifuged at 14000 rpm for 3 minutes. The yielded 
concentrations of DNA were measured using spectrophotometer. 
 
3.5 Genotyping of the adiponutrin (PNPLA3) variant  
The adiponutrin coding single nucleotide polymorphism (SNP) p.I148M (rs738409) 
(Romeo S 2008, Tian C 2010, Sticke F 2011 ) was genotyped using a solution-phase 
hybridization reaction with 5'-nuclease and fluorescence detection in the 7300 Real-
Time PCR system (Applera, Norwalk, CT). Primer and probe sequences are listed in 
Table 2. 
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The PCR reactions (25 µL) contained:  
- 20 ng of DNA  
- 900 nM of each primer 
- 1 × TaqMan Universal Master Mix  
- 200 nM of VIC-labelled MGB/NFQ probes  
- 200 nMof FAM-labelled MGB/NFQ probes. 
Abbreviation: MGB/NFQ – minor groove binder/non-fluorescent quencher. 
 
Table 2 
Primer and probe sequences 
Primer / probe Sequence 
Forward primer 5’ – AACTTCTCTCTCCTTTGCTTTCACA – 3’ 
Reverse primer 5’ – TCTACAGTGGCCTTATCCCTCC – 3’ 
VIC 5’ – TTCCTGCTTCATGCC – 3’ 
FAM 5’ – CCTGCTTCATCCC – 3’ 
  
 
The 96-well plates were used. In 84 wells 2 µl of genomic DNA was disposed. In four 
wells 2 µl of buffer alone without DNA were pipetted (i.e. the negative control wells), in 
the remaining 8 wells (i.e. positive control wells) only genomic DNA was disposed. After 
addition of the PCR mix, the plate was covered with the PCR plate sealer and briefly 
centrifuged in the plate centrifuge.  
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The PCR amplification conditions were as follows:   
 
Pre-read run    2 minutes  60 ° C  1 cycles 
DNA denaturation    10 minutes  95 ° C   1 cycles 
Amplification phase I   15 seconds   95 ° C  40 cycles 
Amplification phase II  1 minute  60 ° C  40 cycles 
Post-read run   1 minute  60 ° C  1 cycle 
 
The results were analysed using the allelic discrimination software (SDS version 2.0.5) 
as shown in example in Figure 4. To ensure genotyping quality, we included negative 
controls and DNA samples with known PNPLA3 genotypes as internal controls. 
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Figure 4. Allelic discrimination plot. The diagram presents the results of SNP genotyping 
with a solution-phase hybridization reaction including two dye-labelled probes and 5'-
nuclease and fluorescence detection in the 7300 Real-Time PCR system (see Methods). 
Red and blue dots represent homozygous carriers of the variant, heterozygous 
individuals are marked in green.  
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3.6 Statistical analysis 
Allele and genotype frequencies of the adiponutrin (PNPA3) SNP p.I148M were tested 
for consistency with Hardy-Weinberg equilibrium (HWE) using an exact test 
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Median liver stiffness values among carriers of the 
[CC], [GC] and [GG] genotypes were compared by Kruskal-Wallis non-parametric 
analysis of variance (ANOVA) and Mann-Whitney U tests. The relationship between liver 
stiffness and the adiponutrin variant as well as other potentially profibrogenic factors 
(age, BMI, gender, hepatitis C virus (HCV) genotype) was assessed by univariate and 
multivariate linear regression analysis. Only variables that were significant in the 
univariate analysis were included in the multivariate model.  
The association between the SNP p.I148M and liver cirrhosis, as defined by liver 
stiffness ≥ 13.0 kPa (Friedrich-Rust M 2008), was analyzed in contingency tables. Allele 
frequency differences were assessed by χ2 test and genotype differences by Armitrage's 
trend test (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). The effects of the 
adiponutrin SNP and the other potential profibrogenic factors on the development of 
cirrhosis were further estimated by unvariate and multivariate logistic regression 
analysis. The population attributable fraction (PAF) was calculated using PARC software 
(http://www.miner.rochester.edu/cpm/education/ match/productspubs.html) (Grünhage F 
2007). 
Unless stated specifically, all statistical analyses was performed with SPSS 18.0 
(SPSS, Munich, Germany) and two-sided P values < 0.05 were regarded as significant. 
Phenotypic quantitative data were expressed as medians and ranges and analysed 
using Mann-Whitney U tests. Frequencies of qualitative phenotypes were analysed 
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using contingency table statistics. Elastography results were analysed for correlation 
with fibrosis stages applying Spearman ρ tests. 
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4. RESULTS 
 
4.1 Fibrosis staging with elastography is in line with liver histology 
In total, 229 individuals underwent both transient elastography and percutaneous liver 
biopsy (Table 3). No major complications of the latter procedure were recorded. As 
reported by others (Pinzani 2008, Castéra L 2010c), a direct comparison of liver 
stiffness and histological fibrosis stages showed a close correlation between both 
methods (Spearman's ρ = 0.743, P < 0.01). Further regression analysis demonstrated 
that in our overall cohort, liver stiffness values were not affected by liver inflammation as 
assessed by serum ALT activities (P > 0.05).  
An exploratory analysis of the patients who underwent liver biopsy (Table 3) in 
comparison to the remaining patients (Table 1) showed a significantly higher prevalence 
of cirrhosis and deteriorated liver function, as indicated by significantly higher bilirubin 
and INR levels as well as lower serum albumin and platelets concentrations; the 
biopsied patients were significantly older and comprised more women as compared to 
the other patients (all P < 0.05). 
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Table 3 
Clinical characteristics of the individuals scheduled for liver biopsy 
Variables  Subject characteristics  
N (male / female) 229 (122 / 107)* 
Age (years) 53 (20 - 78)* 
BMI (kg/m2) 24.4 (16.1 - 38.8) 
Alcohol consumption (g/24 h)§ 0 (0 - 40) / mean ± SD: 5.2 ± 10.7 
Overt cirrhosis 114 (49.8%)* 
Liver biopsy 
   Specimen length (mm) 
 
22 (7 - 79) 
   Stage of fibrosis 
      0 
      1 
      2 
      3 
      4 
 
20 (8.7%) 
  50 (21.8%) 
  24 (10.5%) 
18 (7.9%) 
117 (51.1%) 
Transient elastography 
   Liver stiffness (kPa) 
   ≥ 13.0 kPa (N) 
 
11.3 (2.2 - 75.0)* 
108* 
Bilirubin (mg/dL) 
Creatinine (mg/dL) 
INR 
MELD 
Albumin (g/L) 
ALT (U/L) 
Gamma-GT (U/L) 
Glucose (mg/dL) 
Platelets (×109/l) 
   0.9 (0.2 - 6.0)* 
  0.8 (0.5 - 5.1) 
   1.1 (0.9 - 2.1)* 
  8 (6 - 31)* 
41 (3 - 56)* 
48 (5 - 341) 
      80 (13 - 2597)* 
  98 (60 - 195) 
  177 (23 - 477)* 
Values are given as medians (ranges), unless stated otherwise. 
* P < 0.05 in exploratory comparison to the remaining patients who underwent elastography only (Mann-
Whitney U tests or contingency table statistics). § during the 12 months prior to transient elastography. 
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; gamma-GT, γ-glutamyl transferase; 
INR, international normalised ratio; MELD, model of end-stage liver disease. 
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4.2 The adiponutrin variant p.I148M increases fibrosis levels    
Overall, genotyping success rate was 100%. In total, the frequencies of the [C] allele 
(p.I148) and the [G] allele (p.148M) were 73.5% and 26.5%, respectively. The 
genotypes [CC], [GC] and [GG] genotypes were carried by 485, 351 and 63 individuals, 
respectively. All allele and genotypes frequencies were consistent with HWE (Figure 5) 
and in line with frequencies deposited in the Entrez SNP database 
(http://www.ncbi.nlm.nih.gov/snp). Liver stiffness was successfully determined in 899 of 
1,000 recruited patients, i.e. 10% of patients were excluded from the study due to 
unreliable or failed elastography (see Methods). The most common reasons were 
massive and/or perihepatic ascites or obesity (BMI > 30 kg/m2, increased waist 
circumference). 
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Figure 5. De Finetti diagram with Hardy-Weinberg parabola for the PNPLA3 p.I148M 
polymorphism. The diagram illustrates genotype and allele frequencies in cases 
(individuals with liver stiffness ≥ 13.0 kPa, blue line) and "controls" (stiffness < 13.0 kPa, 
black line). Frequencies of the [C] allele are shown at the intersection between the 
vertical dotted line and the bottom perpendicular. The frequencies of [GG] and [CC] 
homozygotes are depicted on the left and right diagonal axes, respectively, whereas the 
frequency of [GC] heterozygous PNPLA3 patients is plotted on the vertical axis on the 
left. Genotype frequencies in cases and controls plot on the diagram’s parabola, i.e. they 
are in HWE (both P > 0.05). The distinctive intersections of the blue and black vertical 
doted lines with the bottom perpendicular illustrate that the risk allele frequency is 
significantly (P < 0.05) higher in cases as compared to controls (P < 0.05). 
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Figure 6 shows that median liver stiffness differed significantly (P = 0.017 by non-
parametric ANOVA) among the three groups. Whereas carriers of the genotype [CC] 
presented with median liver stiffness of 6.3 kPa (range 2.3 - 75.0), [GC] and [GG] 
carriers displayed 6.8 kPa (range 2.2 - 75.0) and 7.5 kPa (range 2.2 - 75.0), 
respectively. Hence, carriers of the [G] allele were predisposed to develop more 
advanced liver fibrosis.  
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Figure 6. Box-and-Whisker plots illustrating liver fibrosis as phenotyped by transient 
elastography (liver stiffness) in carriers of distinct adiponutrin genotypes (PNPLA3 
p.I148M). Due to the skewed distribution of stiffness values ranging up to 75.0 kPa (see 
Figure 7), all values were log transformed. Liver stiffness values differ significantly 
(P = 0.017, non-parametric ANOVA) between carriers of distinct adiponutrin genotypes. 
In particular, patients carrying [GC] or [GG] genotypes, previously reported to represent 
risk factors for fatty liver (Romeo S 2008) and alcoholic liver disease (Tian C 2010, 
Sticke F 2011), display significantly (*, P = 0.039) more advanced liver fibrosis than 
patients with genotype [CC]. 
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Figure 7 illustrates the distribution of liver stiffness in our cohort, stratified for carriers of 
the adiponutrin risk allele [G] (red bars) and non-carriers of this allele (green bars), and 
demonstrates that risk genotypes were more prevalent among individuals with increased 
liver stiffness.  
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Figure 7. Histogram illustrating the distribution of liver stiffness values stratified for 
adiponutrin variants. Red bars represent patients with at-risk adiponutrin genotypes [GC 
and GG] and individuals with the low risk genotype [CC] are presented with green bars. 
For each liver stiffness value (rounded to the closest integer), the absolute numbers of 
patients (N) are shown. Carriers of the risk allele prevail among individuals with higher 
liver stiffness values, whereas the low risk genotype is more prevalent in patients with 
mild fibrosis. 
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Linear regression analysis demonstrated that the adiponutrin variant (P < 0.01), age 
(P < 0.001) and alcohol consumption (P < 0.01) significantly increased liver stiffness in 
our cohort. No association was found between liver fibrosis and other potential 
profibrogenic factors (see Methods). Subsequent multivariate analysis identified age 
(P < 0.001), alcohol consumption (P < 0.01) and the adiponutrin variant (P < 0.01) as 
independent risk factors for enhanced liver fibrosis. However restricting the analysis to 
the subgroup of 229 patients who underwent liver biopsy, we did not detect a statistically 
significant association between variant adiponutrin and histological fibrosis stages (P > 
0.05). 
 
4.3 Carriers of variant adiponutrin are at high risk of developing liver cirrhosis 
To further ascertain our results, we compared allele and genotypes frequencies between 
patients with and without liver cirrhosis using contingency tables. Table 4 and Figure 5 
show that there is a significant association between the adiponutrin variant and liver 
stiffness values that indicate the presence of cirrhosis (i.e., ≥ 13.0 kPa) (Friedrich-Rust 
M 2008). Indeed, both homo- and heterozygous carriers of the risk allele [G] showed an 
increased risk of developing liver stiffness above the threshold for cirrhosis (OR = 1.57, 
95% CI = 1.14 - 2.15, P = 0.005). Accordingly, Table 4 shows that carriers of the 
p.I148M risk genotypes [GC] and [GG] were significantly (P = 0.002) overrepresented 
among cases (55%) with respect to controls (43%).  
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Table 4 
 Distribution of alleles and genotypes for PNPLA3 p.I148M and association tests   
Counts of alleles / genotypes PNPLA3 p.I148M             
allele / genotype 
Controls (2N = 1396) Cases (2N = 402) 
C 1049 (0.75) 272 (0.68) 
G  347 (0.25) 130 (0.32) 
CC  394 (0.57) 91 (0.45) 
GC  261 (0.37)  90 (0.45) 
GG    43 (0.06)  20 (0.10) 
Association tests χ2 P 
Allele frequency difference test 8.96 0.002 
Armitrage’s trend test 8.98 0.002 
OR statistics OR 95% CI 
[G] ↔ [C] 1.445 1.135 - 1.840 
[GG] ↔ [GC] 1.493 1.073 - 2.078 
[GG] ↔ [GC + CC] 1.683 0.966 – 2.933 
[GC + GG] ↔ [CC] 1.567 1.143 - 2.148 
Patients with cirrhosis as defined by liver stiffness values ≥ 13.0 kPa were regarded as cases. 
[G] represents the fibrosis risk allele. 
Abbreviations: CI, confidence interval; I, isoleucine; M, methionine; OR, odds ratio; p, protein 
(amino acid number); PNPLA3, adiponutrin. 
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Table 5A summarizes the results of univariate logistic regression analysis, 
demonstrating that the p.I148M variant, age and alcohol consumption, but neither BMI 
nor gender significantly affect the development of liver cirrhosis. Irrespectively of the 
known associations between HCV genotypes 2 and 3 and non-alcoholic fatty liver 
disease (Cheung O 2008), fibrosis levels in the subgroup of patients with chronic HCV 
infection were not affected by HCV genotype. The inclusion of the adiponutrin variant, 
age and alcohol consumption in multivariate regression analysis (Table 5B) confirmed 
independent effects for the adiponutrin variant (OR = 1.86, P = 0.001) age (OR = 1.03, 
P < 0.001) and alcohol (OR = 1.001, P = 0.001) on liver cirrhosis.  
 
The phenotypic characterization of liver fibrosis by elastography allowed us to perform a 
sensitivity analysis, as depicted in Figure 8. For this analysis, we calculated the OR of 
developing advanced fibrosis in homo- and heterozygous carriers of the [G] allele in 
comparison to [CC] homozygotes. At first we divided the study cohort into two 
subgroups, using different elastography cut-offs from 3.0 to 75.0 kPa. Individuals with 
liver stiffness values below the given cut-off were assigned as "controls", whereas 
carriers of the higher values were regarded as cases. Figure 8 illustrates that the [G] 
allele increases the risk of liver fibrosis for cut-offs between 12.0 and 40.0 kPa (all 
P < 0.05), resulting in OR between 1.5 and 2.2. On the other hand for liver stiffness cut-
offs < 12.0 kPa and > 40.0 kPa, no significant risk could be detected. 
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Table 5 
Risk factors for developing liver cirrhosis 
(A) Univariate analysis 
Factor OR 95% CI P 
PNPLA3 p.I148M 
Age 
Alcohol 
BMI 
Gender 
HCV genotype 
1.567 
1.033 
1.001 
0.996 
0.781 
0.982 
143 - 2.148 
1.020 - 1.046 
1.000 - 1.002 
0.963 - 1.064 
0.570 - 1.097 
0.797 - 1.210 
0.005 
< 0.001 
0.001 
> 0.05 
> 0.05 
> 0.05 
 
(B) Multivariate analysis 
Factor OR 95% CI P 
PNPLA3 p.I148M 
Age 
Alcohol 
1.860 
1.028 
1.001 
1.295 - 2.673 
1.013 - 1.043 
1.000 - 1.002 
0.001 
< 0.001 
0.001 
Abbreviations: BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus;                  
I, isoleucine; M, methionine; OR, odds ratio; p, protein (amino acid number); PNPLA3, 
adiponutrin. 
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A subgroup analysis of patients with viral hepatitis (chronic HBV and/or HCV infection) 
indicated that only homozygous [GG] carriers were at increased risk for developing 
advanced fibrosis (P < 0.05) and liver stiffness values ≥ 13.0 kPa, indicating the 
presence of cirrhosis (OR = 2.09, 95% CI 1.01 - 4.324, P < 0.05). On the other hand, in 
patients suffering from non-viral hepatitis, both [GG] homozygotes and [GC] 
heterozygotes showed more advanced liver fibrosis than patients with genotype [CC] 
(P < 0.05) and were at risk of cirrhosis (OR = 1.99, 95% CI 1.18 - 3.39, P < 0.05). 
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Figure 8. Odds ratios (OR) for developing advanced liver fibrosis among carriers of the 
[G] allele plotted against liver stiffness cut-off values between 3.0 and 75.0 kPa. 
According to a recent recommendation (Hosseinpoor AR 2010), OR is given on a log 
scale. For stiffness cut-offs between 12.0 and 40.0 kPa, the [G] allele of the adiponutrin 
variant p.I148M represents a significant risk factor for fibrosis. 
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4.4 Variant adiponutrin contributes to 16% of total cirrhosis risk 
From the results of the association study (Table 4), we calculated the population 
attributable fraction (PAF), i.e. the proportion of the cirrhosis incidence in our population 
that is due to the adiponutrin risk allele. In other words, PAF corresponds to the fraction 
of cirrhosis cases that would be eliminated if exposure to the variant was absent. Based 
on OR = 1.56 (Table 4), the PAF for homo- and heterozygous carriers of the risk allele is 
0.160, i.e. the p.I184M variant contributes 16.0% to the total cirrhosis risk. 
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5. DISCUSSION 
 
So far only a limited number of genes influencing liver fibrogenesis and no common 
hepatic fibrosis risk gene have been identified. Herein, we analyze the adiponutrin 
polymorphism p.I148M, previously identified as genetic risk factor for severe forms of 
NAFLD and ALD. Our results indicate that variant adiponutrin confers an increased risk 
for developing advanced liver fibrosis and cirrhosis in patients with chronic liver 
diseases.  
Functional adiponutrin studies remain inconclusive. For example He et al. (He S 
2010) demonstrated that the amino acid substitution at position 148 of the adiponutrin 
molecule affects its catalytic activity and that expression of the variant enzyme increases 
the cellular triglyceride content in cultured hepatocytes and mouse livers. Hence, 
carriers of the risk allele may display a genetic predisposition to lipotoxicity and hepatic 
inflammation, nourishing chronic liver injury (Sookoian S 2009). On the other hand, 
latest studies from two other groups (Chen W 2010, Basantani MK 2011) argue against 
an association between general PNPLA3 deficiency and NAFLD. Indeed, deletion of 
Pnpla3 in mice did neither affect triglyceride hydrolysis or glucose levels nor energy 
homeostasis and did not increase liver steatosis or inflammation (Basantani MK 2011). 
Likewise, no metabolic effects were found in Pnpla3 knockout mice fed a methacholine-
deficient diet or additionally challenged with leptin deficiency (Chen W 2010). On the 
other hand, computer modelling implies that the substitution of isoleucine by methionin 
at amino acid position 148 alters substrate access to the catalytic serine residue and 
results in the loss of triglyceride hydrolysis activity (He S 2010). Such discrepancies 
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between genetic analyses in large cohorts, computer modelling and results in mouse 
models might be attributed to species-specific functions of adiponutrin. Therefor, further 
studies are needed before results from adiponutrin loss-of-function murine models can 
be directly extrapolated to humans carrying the PNPLA3 risk variant.   
Here, we entertain that patients with chronic liver diseases who possess the risk 
variant of adiponutrin are more likely to develop progressive fibrosis and cirrhosis. Of 
note, our cohort encompasses patients suffering from a variety of common chronic liver 
diseases (Table 1), and subgroup analyses of patients with chronic viral hepatitis and 
non-viral liver diseases provided uniform association results. In contrast to the cohort 
published by Tian et al. (Tian C 2010), which encompassed patients with very high 
ethanol intake, we excluded patients with significant alcohol consumption (see 
Methods). Since PNPLA3 has been showed to affect liver fat contents in NAFLD and 
ALD (Kantartzis K 2009, Kotronen A 2009a, Sookoian S 2009, Romeo S 2010, 
Wagenknecht LE 2011), variant adiponutrin could promote liver injury and accelerate 
fibrosis only in the setting of additional cofactors, in particular alcohol (Poynard T 1997, 
Bellentani S 1999). Therefore, we performed uni- and multivariate analyses (see Results 
and Table 5), which indicated that both the gene variant and alcohol represent 
independent profibrogenic risk factors. Our findings support the hypothesis that the 
PNPLA3 variant p.I148M represents a general susceptibility factor for hepatic fibrosis in 
patients with chronic liver diseases. 
Noteworthy, this is the first genetic study investigating liver fibrosis in which a 
large cohort of patients was phenotyped non-invasively by transient elastography. As 
pointed out by the International Fibrosis Group (McHutchison J 2006), liver biopsy 
represents a substantial barrier for clinical trials in fibrosis, and this group recommended 
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that accurate, standardized, non-invasive tests would be helpful to optimize the design 
of antifibrotic studies. In our study, the correlation between liver stiffness and histological 
fibrosis stages was in line with the latest results by Wong et al. (Wong VW 2010), who 
demonstrated that neither inflammation grade nor NAFLD activity score affect the overall 
accuracy of transient elastography appreciably. Furthermore, the correlation even 
exceeded the correlation between fibrosis stages and collagen contents as assessed by 
morphometric image analysis (Goodman ZD 2009). The lack of association between 
adiponutrin and histological fibrosis stages in the subgroup of our patients who 
underwent liver biopsy might be related to several factors: Firstly, the risk allele [G] has 
a frequency of ~ 20% in the European population but causes only moderate fibrosis risk, 
as is to be expected for a complex multifactorial trait (Zondervan KT 2004). In our 
cohort, the p.I148M variant allele confers an OR of ~ 1.6 for developing liver cirrhosis 
(Table 5), which is close to the risk of 1.8 reported by Tian et al. (Tian C 2010) for 
patients with ALD. Accordingly, the inclusion of variant adiponutrin in a novel equation 
for predicting NAFLD and NASH in the general population does not substantially 
improve the area-under-the-curve (AUC) statistics in comparison to environmental 
factors (Kotronen A 2009b). Although fibrosis stages in patients who underwent liver 
biopsy (Table 3) were shifted towards cirrhosis as compared to the total study cohort 
(prevalence 51.1% versus 22.3%, Table 1), our group of 229 patients who underwent 
liver biopsy has limited statistical power, which strongly depends on allele frequency and 
OR, demonstrating further the usefulness of large non-invasively phenotyped cohorts for 
adequately powered association studies in liver fibrosis (Bataller R 2003).  
Secondly, the lack of association might be due to the technical limitations of 
transient elastography and liver biopsy. In our study, the median length of the biopsies 
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(Table 3) was adequate according to the German consensus guidelines (Schirmacher P 
2004), but not all biopsies were > 15 - 25 mm (Bedossa P 2003). Although elastography 
appears to be a highly accurate method for the diagnosis of cirrhosis, liver abnormalities 
independent of fibrosis can influence stiffness (Castéra L 2010b), and obesity as well as 
other features of the metabolic syndrome contribute to elastography failure and 
unreliable results (Castéra L 2010a). Recently Castéra and Pinzani (Castéra L 2010c) 
pointed to the limitation of elastography for intermediate stages of liver fibrosis, a finding 
already reported in chronic viral hepatitis (Afdhal NH 2009). 
In this setting, the sensitivity analysis (Figure 8) adds further value. Indeed, 
histological staging of liver fibrosis provides a semi-qualitative scale (F0 - F4), whereas 
elastography measurements represent continuous quantitative data with values ranging 
from 2.2 to 75.0 kPa (Table 1). Interestingly, this analysis revealed a significant 
association between the risk allele [G] and increased hepatic fibrosis for a wide range of 
liver stiffness cut-off values and a trend for all stiffness values above the normal range. 
The lack of association at values < 12.0 and > 40.0 kPa may underline the decreased 
accuracy of elastography for these fibrosis stages (Castéra L 2010c), but could also 
reflect the presence of additional determinants that affect initiation or decompensation of 
hepatic fibrosis. Additionally, the risk of developing liver cirrhosis in patients with chronic 
viral hepatitis was increased only for homozygous carriers of the risk allele, indicating 
that in this subgroup of patients the marked profibrogenic effect of the viral infection per 
se might override the dose effect of adiponutrin genotype depicted in Figure 6.  
Although several diverse triggers can lead to hepatic fibrogenesis, this process 
always shares the same features: In case of chronic injury, progression from 
compensated to decompensated disease is inevitable (Bataller R, JCI 2005). 
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Progressive deterioration of hepatic function either leads to liver transplantation or 
patient’s death, in some cases hepatic malignancy develops. Interestingly, individuals 
with comparable risk profiles do not necessarily display the same risk of developing liver 
cirrhosis. Indeed, liver fibrogenesis is a complex (i.e. multifactorial) process governed by 
multiple genetic factors and their interactions with numerous environmental triggers. 
These genetic factors, which to date remain mostly unknown, have for long been 
suspected as critical determinants of chronic liver disease. With respect to the 
increasing mortality rates due to liver cirrhosis, prompt identification of risk variants is 
crucial for the development of novel antifibrotic drugs, planning of tailored preventive 
strategies as well as early identification of at-risk individuals. Our results show that the 
PNPLA3 p.I148M common polymorphism represents a serious thread for patients with 
chronic liver diseases. It can be anticipated that dedicated studies investigating 
regulators of adiponutrin expression could unravel further polymorphisms affecting liver 
fibrogenesis. This might lead to personalized antifibrotic strategies targeting adiponutrin-
mediated pathways in genetically defined at-risk patients. 
In summary, this study shows that variant adiponutrin is associated with 
progressive fibrosis and cirrhosis in patients with chronic liver diseases. Hence, we 
might consider genetic screening of individuals with chronic liver disease for the risk 
PNPLA3 variant p.148M. For these patients, careful and timely follow-up should be 
performed to detect rapid progression of liver fibrosis. Based on our results, this could 
be accomplished by evaluation of liver fibrosis with non-invasive elastography. As stated 
in our recent review (Krawczyk M 2010b), such results might soon be applied in clinical 
practice. As the costs of genotyping are decreasing dramatically, and currently do not 
exceed 0.00001 Euro per polymorphism per patient, even whole-genome sequencing 
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becomes available for patients. Hence, we envision prospective studies to validate the 
combination of genotyping risk variants and elastography for individualized prediction of 
cirrhosis risk. 
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